FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089322121> ?p ?o ?g. }

• W3089322121 endingPage "6127" @default.
• W3089322121 startingPage "6116" @default.
• W3089322121 abstract "Aberrant MYC and BCL2 expression, cell of origin (COO), and National Comprehensive Cancer Network international prognostic index (NCCN-IPI) are commonly used for risk assessment and treatment decision in patients with diffuse large B-cell lymphoma (DLBCL). Although obesity has been shown to be of predictive value in DLBCL patients, it remains unclear whether it retains its prognostic relevance after those aforementioned novel factors being taken into consideration.Patients with DLBCL were identified retrospectively in a single institute and data were collected through electronic databases and pharmacy records.Fifteen (17.6%) out of the 85 patients with DLBCL in our cohort were categorized as obese. They had lower platelet counts, were younger and more likely to harbor either BCL2- or MYC-overexpressing tumors. The NCCN-IPI scores, COO, and other clinical parameters were not significantly different between obese and non-obese patients. In spite that obesity adversely affected the treatment response to immunochemotherapy, multivariate analysis showed that only NCCN-IPI risk categories [hazard ratio (HR) 2.83 for high-intermediate or high-risk, versus low-intermediate or low-risk, P=0.034] and BCL2/MYC expressional status (HR 4.12 for BCL2high and/or MYChigh, versus both low expressors, P=0.004) independently predicted progression-free survival (PFS) outcome, whereas obesity lost its prognostic value in this regard (HR 1.81 for obese patients, P=0.242). Similarly, high-intermediate to high NCCN-IPI risk (HR 3.11, P=0.034) and increased expression in either BCL2 or MYC (HR 5.63, P=0.001) both portended an inferior overall survival (OS), but the presence of obesity did not affect the outcome (HR 1.65, P=0.352).Our study has demonstrated that, for the first time, obesity increases the frequency of BCL2- or MYC-overexpressing tumors in patients with DLBCL." @default.
• W3089322121 created "2020-10-01" @default.
• W3089322121 creator A5001749057 @default.
• W3089322121 creator A5039390682 @default.
• W3089322121 creator A5050362941 @default.
• W3089322121 creator A5050473175 @default.
• W3089322121 creator A5057573947 @default.
• W3089322121 creator A5060346883 @default.
• W3089322121 creator A5072811182 @default.
• W3089322121 creator A5075207633 @default.
• W3089322121 creator A5079624990 @default.
• W3089322121 creator A5082863782 @default.
• W3089322121 creator A5084566153 @default.
• W3089322121 creator A5088455920 @default.
• W3089322121 date "2020-10-01" @default.
• W3089322121 modified "2023-10-16" @default.
• W3089322121 title "Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma" @default.
• W3089322121 cites W1513833217 @default.
• W3089322121 cites W1912693401 @default.
• W3089322121 cites W1971815003 @default.
• W3089322121 cites W1976564639 @default.
• W3089322121 cites W1976976340 @default.
• W3089322121 cites W1996451338 @default.
• W3089322121 cites W2015739063 @default.
• W3089322121 cites W2018071905 @default.
• W3089322121 cites W2024819242 @default.
• W3089322121 cites W2044306036 @default.
• W3089322121 cites W2044633729 @default.
• W3089322121 cites W2063691874 @default.
• W3089322121 cites W2067043232 @default.
• W3089322121 cites W2068343048 @default.
• W3089322121 cites W2095064018 @default.
• W3089322121 cites W2097561270 @default.
• W3089322121 cites W2102902239 @default.
• W3089322121 cites W2106674962 @default.
• W3089322121 cites W2109914572 @default.
• W3089322121 cites W2119272690 @default.
• W3089322121 cites W2123018120 @default.
• W3089322121 cites W2131591460 @default.
• W3089322121 cites W2135511903 @default.
• W3089322121 cites W2137293646 @default.
• W3089322121 cites W2145257542 @default.
• W3089322121 cites W2147246240 @default.
• W3089322121 cites W2158267770 @default.
• W3089322121 cites W2159862107 @default.
• W3089322121 cites W2229366053 @default.
• W3089322121 cites W2329713136 @default.
• W3089322121 cites W2472578506 @default.
• W3089322121 cites W4205736005 @default.
• W3089322121 doi "https://doi.org/10.21037/tcr-20-1362" @default.
• W3089322121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35117223" @default.
• W3089322121 hasPublicationYear "2020" @default.
• W3089322121 type Work @default.
• W3089322121 sameAs 3089322121 @default.
• W3089322121 citedByCount "0" @default.
• W3089322121 crossrefType "journal-article" @default.
• W3089322121 hasAuthorship W3089322121A5001749057 @default.
• W3089322121 hasAuthorship W3089322121A5039390682 @default.
• W3089322121 hasAuthorship W3089322121A5050362941 @default.
• W3089322121 hasAuthorship W3089322121A5050473175 @default.
• W3089322121 hasAuthorship W3089322121A5057573947 @default.
• W3089322121 hasAuthorship W3089322121A5060346883 @default.
• W3089322121 hasAuthorship W3089322121A5072811182 @default.
• W3089322121 hasAuthorship W3089322121A5075207633 @default.
• W3089322121 hasAuthorship W3089322121A5079624990 @default.
• W3089322121 hasAuthorship W3089322121A5082863782 @default.
• W3089322121 hasAuthorship W3089322121A5084566153 @default.
• W3089322121 hasAuthorship W3089322121A5088455920 @default.
• W3089322121 hasBestOaLocation W30893221211 @default.
• W3089322121 hasConcept C121608353 @default.
• W3089322121 hasConcept C126322002 @default.
• W3089322121 hasConcept C143998085 @default.
• W3089322121 hasConcept C167135981 @default.
• W3089322121 hasConcept C207103383 @default.
• W3089322121 hasConcept C2778476033 @default.
• W3089322121 hasConcept C2778559949 @default.
• W3089322121 hasConcept C2779338263 @default.
• W3089322121 hasConcept C38180746 @default.
• W3089322121 hasConcept C44249647 @default.
• W3089322121 hasConcept C50382708 @default.
• W3089322121 hasConcept C71924100 @default.
• W3089322121 hasConcept C72563966 @default.
• W3089322121 hasConceptScore W3089322121C121608353 @default.
• W3089322121 hasConceptScore W3089322121C126322002 @default.
• W3089322121 hasConceptScore W3089322121C143998085 @default.
• W3089322121 hasConceptScore W3089322121C167135981 @default.
• W3089322121 hasConceptScore W3089322121C207103383 @default.
• W3089322121 hasConceptScore W3089322121C2778476033 @default.
• W3089322121 hasConceptScore W3089322121C2778559949 @default.
• W3089322121 hasConceptScore W3089322121C2779338263 @default.
• W3089322121 hasConceptScore W3089322121C38180746 @default.
• W3089322121 hasConceptScore W3089322121C44249647 @default.
• W3089322121 hasConceptScore W3089322121C50382708 @default.
• W3089322121 hasConceptScore W3089322121C71924100 @default.
• W3089322121 hasConceptScore W3089322121C72563966 @default.
• W3089322121 hasIssue "10" @default.
• W3089322121 hasLocation W30893221211 @default.
• W3089322121 hasLocation W30893221212 @default.

• next